^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

    Published date:
    12/16/2022
    Excerpt:
    In patients with PD-L1-high expression, OS was comparable between durvalumab and the EXTREME regimen. Durvalumab alone, and with tremelimumab, demonstrated durable responses and reduced TRAEs versus the EXTREME regimen in R/M HNSCC.
    DOI:
    10.1016/j.annonc.2022.12.008
    Trial ID:
    KESTREL
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

    Published date:
    05/13/2020
    Excerpt:
    Pts with low PD-L1 and low TMB had worse OS compared to pts with high PD-L1 or high TMB.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6548
    Test:
    VENTANA PD-L1 (SP263) Assay